Research map: Clinical Outcomes of Lenvatinib–Pembrolizumab in a High-Risk, Dual ICI-Refractory Melanoma Cohort

Back to the article

Papers in this map

  1. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) · E. A. Eisenhauer · 2008 · 30146 citations · Cited by this paper
  2. Augmented Reality Navigation-Assisted Laparoscopic Hepatectomy: A Retrospective Comparison of Anatomical and Non-anatomical Resection · 2026 · Related
  3. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy · Padmanee Sharma · 2017 · 5702 citations · Cited by this paper
  4. Serum Cystatin S (CST4): A Novel Prognostic Marker for Gastric Cancer · 2025 · Related
  5. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma · Jesse Meir Zaretsky · 2016 · 3296 citations · Cited by this paper
  6. Effectiveness of Second-Line Pembrolizumab Monotherapy for the Treatment of Nonsmall Cell Lung Cancer: A Retrospective-Single Institution Study of 52 Vietnamese Patients · 2025 · Related
  7. CTCAE versión 5.0. Evaluación de la gravedad de los eventos adversos dermatológicos de las terapias antineoplásicas · Azael Freites‐Martínez · 2020 · 900 citations · Cited by this paper
  8. Concurrent Tumor-Treating Fields and Chemoradiotherapy: Outcomes in Grade 4 Glioma Patients · 2025 · Related
  9. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study · Robert John Motzer · 2024 · 177 citations · Cited by this paper
  10. Risk Factors for Febrile Neutropenia in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Undergoing Initial R-CHOP Treatment · 2026 · Related
  11. NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024 · Susan M. Swetter · 2024 · 158 citations · Cited by this paper
  12. Contribution of TP53 and MDM4 Genetic Polymorphisms as a Risk Factor in Non-Hodgkin Lymphoma in Adult Egyptian Patients · 2025 · Related
  13. Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775 · Vicky Makker · 2023 · 157 citations · Cited by this paper
  14. The Effect of Bladder and Rectum Volume Changes on Exposed Organ Volume During Intensity-Modulated Radiotherapy for Cervical Cancer · 2025 · Related
  15. Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination · Ana Maria Arance · 2022 · 131 citations · Cited by this paper
  16. Mechanism and Therapeutic Progress of One-Carbon Metabolic Key Enzyme: Serine Hydroxymethyltransferase 2 in Cancer · 2025 · Related
  17. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2024 · Claus Garbe · 2024 · 92 citations · Cited by this paper
  18. Enfortumab Vedotin Plus Pembrolizumab Compared to Pembrolizumab and Standard Chemotherapy: Birds of a Feather Flock Together in Urothelial Cancer · 2025 · Related
  19. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024 · Claus Garbe · 2024 · 74 citations · Cited by this paper
  20. Stage Migration and Validity of the International Federation of Gynecology and Obstetrics (FIGO) 2018 Staging System for Cervical Cancer: A Retrospective Cohort Study From a Tertiary Cancer Center in · 2025 · Related
  21. Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study · Georgina Venetia Long · 2025 · 55 citations · Cited by this paper
  22. Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study · Theresa Michelle Medina · 2025 · 55 citations · Cited by this paper
  23. Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study · Antonio González-Martı́n · 2024 · 24 citations · Cited by this paper
  24. Effectiveness of radiotherapy in delaying treatment changes in primary or secondary immunorefractory oligoprogressive patients: preliminary results from a single-center study · Valentina Zagardo · 2024 · 14 citations · Cited by this paper
  25. Emerging Therapies in the Treatment of Advanced Melanoma · Sameer Massand · 2021 · 13 citations · Cited by this paper
  26. Lenvatinib enhances antitumor immunity of anti-PD-1 antibody · Yu Kato · 2025 · 12 citations · Cited by this paper
  27. Real-world outcomes of combined lenvatinib and anti-PD-1 in advanced melanoma: the Lenvamel study, a multicenter retrospective study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée) · Perrine Rousset · 2024 · 6 citations · Cited by this paper
  28. Immunotherapy after progression to double immunotherapy: pembrolizumab and lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition · Georgios Lyrarakis · 2024 · 6 citations · Cited by this paper
  29. Lenvatinib/Pembrolizumab as second line treatment for advanced melanoma patients refractory to programmed death 1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors · Pier Francesco Ferrucci · 2023 · 4 citations · Cited by this paper
  30. Lattice radiotherapy-induced dramatic regression of bulky metastases challenges radioresistance compared with homogeneous hypofractionation in anorectal mucosal melanoma: a case report · Gianluca Ferini · 2025 · 3 citations · Cited by this paper
  31. Untitled · Cited by this paper
  32. Untitled · Cited by this paper

Source: OpenAlex (CC0)